Last edited by Mor
Thursday, July 30, 2020 | History

2 edition of Cardiovascular actions of sulfinpyrazone found in the catalog.

Cardiovascular actions of sulfinpyrazone

basic and clinical research : proceedings of an international symposium, Hamilton, Bermuda, May 21-23, 1979

  • 344 Want to read
  • 24 Currently reading

Published by Symposia Specialists in Miami, FL .
Written in English

    Subjects:
  • Sulfinpyrazone -- Physiological effect -- Congresses.,
  • Cardiovascular pharmacology -- Congresses.,
  • Blood platelets -- Effect of drugs on -- Congresses.

  • Edition Notes

    Statementedited by Maurice McGregor ... [et al.].
    ContributionsMcGregor, Maurice., CIBA-GEIGY Corporation.
    Classifications
    LC ClassificationsRM666.S827 C37
    The Physical Object
    Paginationxv, 342 p. :
    Number of Pages342
    ID Numbers
    Open LibraryOL4438228M
    ISBN 100883721333
    LC Control Number79093243

    Additional color graphics may be available in the e-book version of this book. Library of Congress Catalogi ng- in -Publication Data ISBN: 9 78 -9Author: Rafik Karaman. Cardiovascular disease (CVD), principally heart disease and stroke, is the leading cause of death for both males and females in developed countries. Aspirin is the most widely used and tested antiplatelet drug in CVD, and it is proven to be the cornerstone of antiplatelet therapy in treatment and prevention of CVD in clinical trials in various populations. In acute coronary syndrome Cited by:

    Sulfinpyrazone is a generic medicine name and there are several brands available for it. Some of the brands for sulfinpyrazone might be better known than sulfinpyrazone itself. If the pharmacy that's willing to deliver medicines to your home doesn't have sulfinpyrazone in stock, you can ask for one of the branded alternatives for sulfinpyrazone. WebMD provides common contraindications for Sulfinpyrazone Oral. Find out what health conditions may be a health risk when taken with Sulfinpyrazone Oral.

    Buy Stroke in Atrial Fibrillation, An Issue of Cardiac Electrophysiology Clinics, E-Book (The Clinics: Internal Medicine 6): Read Books Reviews - Sulfinpyrazone reduces serum urate levels, prevents formation of new tophi, and promotes resorption of existing tophi by increasing clearance of uric acid and water through the kidneys. Sulfinpyrazone has been shown to reduce cardiac mortality during the second through the .


Share this book
You might also like
Design Basis Tropical Cyclone for Nuclear Power Plants

Design Basis Tropical Cyclone for Nuclear Power Plants

Acute care of the neonate

Acute care of the neonate

Salute to the soldiers of 1922

Salute to the soldiers of 1922

CCTV, live and videotapes

CCTV, live and videotapes

The long watch

The long watch

Caribou and muskoxen habitat studies

Caribou and muskoxen habitat studies

1 2 3 Numbers of the Bible

1 2 3 Numbers of the Bible

Fundamentals of fuzzy sets

Fundamentals of fuzzy sets

The vvhole booke of Psalmes

The vvhole booke of Psalmes

Louise K. Bard.

Louise K. Bard.

A chicken followed me home!

A chicken followed me home!

On Mucor mucedo, Mucor flavus and related species

On Mucor mucedo, Mucor flavus and related species

Fodors Australia, New Zealand and the South Pacific.

Fodors Australia, New Zealand and the South Pacific.

Cardiovascular actions of sulfinpyrazone Download PDF EPUB FB2

The book is a collection of papers presented at a symposium on sulfinpyrazone, held in Bermuda in May, It is a valuable compendium of up-to-date research on the drug and will be useful to the specialist, but it lacks a comprehensive review of the earlier work with the agent and will therefore be too narrow for the general : Edwin W.

Salzman. Add tags for "Cardiovascular actions of sulfinpyrazone: basic and clinical research: proceedings of an international symposium, Hamilton, Bermuda, May".

Be the first. Similar Items. 2. "Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals, East Hanover, NJ. Braun J "Abnormalities of urinary sediment and renal failure following sulfinpyrazone therapy." Arch Intern Med (): 4. Walls M, Goral S, Stone W "Acute renal failure due to sulfinpyrazone." Am J Med Sci (): / The use of sulfinpyrazone is contraindicated in patients with a current or past history of blood dyscrasias.

Anemia, leukopenia, agranulocytosis, thrombocytopenia, and aplastic anemia have been reported rarely with sulfinpyrazone use.9/   Because Anturane (sulfinpyrazone) is a potent uricosuric agent, it may precipitate urolithiasis and renal colic, especially in the initial stages of therapy.

For this reason, an adequate fluid intake and alkalinization of the urine are recommended. In cases with significant renal impairment, periodic assessment of renal function is indicated. PRODUCT MONOGRAPH SULFINPYRAZONE Sulfinpyrazone Tablets USP mg a) Platelet Inhibitory Agent ACTIONS AND CLINICAL PHARMACOLOGY i) In vitro experiments with SULFINPYRAZONE in human volunteers have demonstrated 1.

The Role of Platelets in. Butler, K.D. and White, A.M.: Inhibition of platelet involvement in the sublethal Forssman reaction by sulfinpyrazone; in McGregor, Mustard, Oliver and Sherry (Eds) Cardiovascular Actions of Sulfinpyrazone: Basic and Clinical Research, pp.

3–17 (Symposium Cited by: Effects of sulfinpyrazone on synthesis of prostaglandins and thromboxanes by platelets in vitro and in vivo McGregor M.

Mustard Jf Oliver Mf Sherry S. Cardiovascular actions of sulfinpyrazone. 37 51 Symposia Specialist Inc Miami 5 Moss Aj Decamilla J. David H. Cardiac death in the first 6 months after myocardial infarction: potential for Cited by: 4. This short monograph has collected together all the current evidence for reversing atherosclerosis.

I feel that the book is one that would be read and appreciated only by those who are deeply interested and committed to the pathophysiology of atherosclerosis and not one that would be valuable for the average clinical physician. Although the arguments are there, they are less than convincing.

Sulfinpyrazone is a uricosuric medication used to treat also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and a: C₂₃H₂₀N₂O₃S.

Sulfinpyrazone is used in the treatment of chronic gout (gouty arthritis), which is caused by too much uric acid in the blood. The medicine works by removing the extra uric acid from the body. Sulfinpyrazone does not cure gout, but after you have been taking it for a few months it may help prevent gout attacks.

Author(s): McGregor,Maurice; CIBA-GEIGY Corporation. Title(s): Cardiovascular actions of sulfinpyrazone: basic and clinical research: proceedings of an international symposium, Hamilton, Bermuda, May/ edited by Maurice McGregor.

Sulfinpyrazone is not a pain reliever. To relieve pain from gout, continue to take your medicines prescribed for pain from gout attacks (e.g., colchicine, ibuprofen, indomethacin) as directed. The purpose of this study was to determine if sulfinpyrazone has a direct action on sympathetic nerve endings to prevent release of the transmitter.

P Cited by: 1. Sulfinpyrazone is an oral uricosuric agent (pyrazolone derivative) used to treat chronic or intermittent gouty pyrazone competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby facilitating urinary excretion of uric acid and decreasing plasma urate concentrations.

This is likely done through inhibition of the urate anion transporter. IUPAC Standard InChIKey: MBGGBVCUIVRRBF-UHFFFAOYSA-N CAS Registry Number: Chemical structure: This structure is also available as a 2d Mol file; Other names.

Sulfinpyrazone is no longer available in the United States. Sulfinpyrazone is a medication primarily used to treat gout. It prevents the occurrence of acute attacks of gout by lowering the levels of uric acid in the body.

It lowers these levels by increasing the excretion of uric acid in the kidneys. Comparative effects of sulfinpyrazone and aspirin in the coronary occlusion-reperfusion dog model. In Cardiovascular Actions of Sulphinpyrazone: Basic and Clinical Research (ed.

McGregor, J. Mustard, M. Oliver and S. Sherry), Symposia Specialists Inc., Miami, pp. –73 Google ScholarAuthor: R. Browning. Sulfinpyrazone is an oral drug that is used to treat gout. Gout is caused by elevated blood levels of uric acid (hyperuricemia).Sulfinpyrazone works by increasing the excretion of uric acid in the urine thereby lowering the elevated levels of uric acid in the blood that are responsible for gout.

We performed a randomized, double-blind, placebo-controlled trial in patients with unstable angina who were hospitalized in coronary care units. Patients received one of four possible treatment regimens: aspirin ( mg four times daily), sulfinpyrazone ( mg Cited by:.

Book. Jan ; Derek Ogston; anticoagulants, aspirin, dipyridamole, ticlopidine, or sulfinpyrazone, combined with cerebrovascular disorders. The antiplatelet and cardiovascular actions of.Allopurinol is a drug that is used to decrease uric acid that causes gout. This lesson will discuss the mechanism of action and structure of allopurinol.Abstract The Anturane Reinfarction Trial is a randomized, double-blind, multicenter clinical trial comparing sulfinpyrazone ( mg four times a day) and placebo in the prevention of cardiac mortal.